CorPath® GRX Neuro Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT04236856

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Siemens Healthineers Endovascular Robotics, Inc. (from the registry)
Registry
  • NCT NCT04236856
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Austria, Canada, France, Spain, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04236856. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-21 (actual); primary completion 2022-04-23 (actual). Results posted on 2025-03-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CorPath® GRX Neuro Study
Condition
Intracranial Aneurysm
Condition
Subarachnoid Hemorrhage
Condition
Headache
Intervention (Device)
Robotic Endovascular Procedure
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04236856
Content hash
e3ba381022c4968b2ed11e6f95c5033d1f3856dc1c82e8e83e395e5331b62415